Sodium bicarbonate, NASOX chemotherapy, and PD-1 immunotherapy delivered directly into the liver for pancreatic cancer metastases.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center Phase II study enrolls adults with pathologically confirmed pancreatic ductal cancer and liver metastases to receive hepatic arterial infusion (HAIC) composed of sequential sodium bicarbonate, NASOX chemotherapy (oxaliplatin and liposomal irinotecan) and an intra-arterial PD-1 inhibitor, with oral S-1 as maintenance. The bicarbonate is infused first to neutralize tumor acidity, followed by chemotherapy and local immunotherapy to increase drug delivery and immune activation within liver lesions. Primary endpoint is overall survival compared to historical controls, with secondary endpoints including response rate, progression-free survival, and safety/tolerability. Interventions are performed by interventional radiology at Ruijin Hospital and patients must meet standard organ-function and performance-status criteria for enrollment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 years and above, with no gender restrictions;
* Pathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium), with metastasis to the liver;
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;
* Adequate organ function, meeting the following criteria:

  a. Hematological tests:
  1. Neutrophils ≥ 1.5 × 10⁹ /L;
  2. White blood cells ≥ 3.0 × 10⁹ /L;
  3. Platelets ≥ 85 × 10⁹ /L;
  4. Hemoglobin ≥ 70 g/L; b. Biochemical tests:

  <!-- -->

  1. Total bilirubin ≤ 2× upper limit of normal (ULN) (for subjects with biliary obstruction, after biliary drainage ≤ 2.5 × ULN);
  2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in metastatic subjects ≤ 5 × ULN;
  3. Albumin level ≥ 28 g/L;
  4. Creatinine clearance rate ≥ 60 ml/min; c. Cardiac function tests:

  <!-- -->

  1. Normal electrocardiogram (ECG) or ECG abnormalities deemed clinically insignificant by the investigator;
  2. Left ventricular ejection fraction (LVEF) ≥ lower limit of normal;
* At least 3 weeks post-surgery, radiotherapy, chemotherapy, or other anti-tumor treatments, with general physical condition or related adverse reactions having recovered (toxicity ≤ grade 1) or stabilized;
* Willing to participate and sign the informed consent form;
* Good compliance and agreement to cooperate with survival follow-up.

Exclusion Criteria:

* Subjects with ascites requiring clinical intervention (including moderate to large amounts of ascites; subjects with ascites need to be stable for more than 4 weeks after drainage);
* Clinically severe gastrointestinal diseases (including bleeding, infectious inflammation, perforation, obstruction, or diarrhea greater than grade 1);
* NRS pain score ≥ 4 after standardized treatment with analgesics;
* Second primary malignancy within 5 years (except cured carcinoma in situ, basal cell, or squamous cell skin cancer; subjects with other previous tumors can be enrolled if there has been no recurrence within 5 years);
* Uncontrolled cardiovascular or cerebrovascular diseases with clinical symptoms, including but not limited to: ① NYHA class III or higher heart failure; ② unstable angina; ③ myocardial infarction or stroke within 6 months; ④ supraventricular or ventricular arrhythmias requiring treatment or intervention; ⑤ uncontrolled hypertension (systolic blood pressure \&gt; 150 mmHg and/or diastolic blood pressure \&gt; 90 mmHg despite optimal treatment);
* Known active hepatitis B subjects (HBsAg positive and HBV DNA ≥ 10³ copies or ≥ 1000 U/ml);
* Active infection or unexplained fever \&gt; 38.5°C during the screening period or on the day of administration (subjects with fever caused by tumors can be enrolled as judged by the investigator), which, in the investigator\&#39;s judgment, would affect the subject\&#39;s participation in this trial or interfere with the evaluation of efficacy;
* Pregnant or breastfeeding women;
* Women of childbearing potential with a positive blood (urine) pregnancy test during the screening period (both male and female subjects should use reliable contraception during the trial and for 3 months after the last dose to prevent pregnancy);
* Subjects with other medical or social issues that, in the investigator\&#39;s judgment, might affect their ability to sign informed consent, participation in the trial, or interpretation of the trial results;
* Patients with an estimated survival time of ≤ 3 months are not included in this study.

Where it's running

• Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Zhongmin Wang
• Email: wzm11896@rjh.com.cn
• Phone: 13901848333

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Energy needs after pancreatic surgery: measuring metabolism to guide nutrition

  This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.

  Recruiting Evangelismos Hospital · Athens, Attica · NCT07703813

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Indocyanine green–guided laparoscopic distal pancreatectomy vs standard approach for pancreatic body/tail lesions

  This trial tests whether using indocyanine green (ICG) fluorescence during laparoscopic distal pancreatectomy helps surgeons protect blood flow and structures, compared with the standard approach, in adults with pancreatic body or tail tumors.

  Recruiting Alexandria University · Alexandria · NCT07656571

• Pancreatic Surgery and New Diabetes Risk in Adults without Diabetes

  This study tests whether removing part or all of the pancreas during surgery affects blood sugar control and metabolism in adults who did not have diabetes before the operation.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT07608055

• Pancreatic Cancer Screen Test in Japan Using the Enzeavour Blood Assay

  This nationwide screening study in Japan tests the Enzeavour Pancreatic Cancer blood test in about 10,000 asymptomatic adults to see if it can help detect pancreatic cancer early.

  Recruiting at 69 sites Cosomil, Inc. · Nagakute, Aichi-ken and 68 other locations · NCT07605819

• NEO-Match nanomechanical testing of pancreatic tumor samples

  This will test whether the NEO-Match® nanomechanical test on biopsy tissue can help predict response to pre-surgery treatment and detect cancer in people with suspected pancreatic tumors.

  Recruiting Artidis Ag · Tampa, Florida · NCT07542041

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.